The significance of platelet-derived growth factors for proliferation of vascular smooth muscle cells

Platelets

Volumn 10, Issue 2-3, 1999, Pages 77-96

  Weber, Artur Aron ^b   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CIPROSTENE; CLOPIDOGREL; CYCLOOXYGENASE 2; DIPYRIDAMOLE; EPIDERMAL GROWTH FACTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; ICOSANOID; LINSIDOMINE; LYSOPHOSPHATIDIC ACID; MITOGENIC AGENT; MOLSIDOMINE; PENTAERYTHRITYL TETRANITRATE; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; SEROTONIN; SOMATOMEDIN; THROMBIN; THROMBIN INHIBITOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ANIMAL MODEL; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL REGENERATION; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; ICOSANOID METABOLISM; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANIMALIA; THROMBUS;

EID: 0032931271     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109909169169     Document Type: Review

References (275)

1. 1. Schwartz SM, Reidy MA. Restenosis. An assessment of factors important in arterial occlusion. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven, 1996: 701-14.
2. 2. Benner KU, Geeren M, Burstedde V, Everts B. Platelet aggregation abnormalities in arterial occlusive diseases (AOD). J Med 1984; 15: 23-33.
3. 3. Davi G, Gresele P, Violi F, Basili ST, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
4. 4. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 96: 983-9.
5. 5. Schrör K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterollowering agents. Eicosanoids 1990; 3: 246-51.
6. 6. Strano A, Davi G, Averna M, Rini GB, Novo S, Difede G, Mattina A, Notarbartolo A. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thromb Haemost 1982; 48: 18-20.
7. 7. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33: 181-94.
8. 8. Braun M, Hohlfeld T, Kienbaum P, Weber A-A, Sarbia M, Schrör K. Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits. Atherosclerosis 1993; 103: 93-105.
9. 9. Weber A-A, Hohlfeld T, Schrör K. ADP-induced second wave aggregation in platelet rich plasma from hypercholesterolemic rabbits. Thromb Res 1991; 64: 703-12.
10. 10. Weber A-A, Hohlfeld T, Strobach H, Schrör K. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1993; 21: 332-8.
11. 11. Friedman RJ, Stemerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML, Spaet TH. The effects of thrombocytopenia on experimental arteriosclerosic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-201.
12. 12. Moore S, Friedman RJ, Singal DP, Gauldie J, Blajchman MA, Roberts RS. Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromh Haemost 1976; 35: 70-81.
13. 13. Fuster V, Bowe EJW, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease. J Clin Invest 1978; 61: 722-30.
14. 14. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
15. 15. Armstrong ML, Peterson RE, Hoak JC, Megan MB, Cheng FH, Clarke WR. Arterial platelet accumulation in experimental hypercholesterolemia. Atherosclerosis 1980; 36: 89-100.
16. 16. Miller DD, Boulet AJ, Tio FO, Garcia OJ, Guy DM, McEver RP, Palmaz JC, Pak KY, Neblock DS, Berger HJ, Daddona PE. In vivo technetium-99m S12 antibody imaging of platelet alpha-granules in rabbit endothelial neointimal proliferation after angioplasty. Circulation 1991; 83: 224-36.
17. 17. Bauters C, Meurice T, Hamon M, McFadden E, Lablanche J-M, Bertrand ME. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835-46.
18. 18. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: 20B-8B.
19. 19. LeBreton H, Topol E, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis. Cardiovasc Res 1996; 31: 235-6.
20. 20. LeBreton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643-51.
21. 21. Schwartz RS, Edwards WD, Huber KC, Antiniades LC, Bailey KR, Camrud AR, Jorgenson MA, Holmes DR. Coronary restenosis: prospects for solution and new perspectives from a porcine model. Mayo Clin Proc 1993; 68: 54-62.
22. 22. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995; 26: 1747-54.
23. 23. Willerson JT, Yao SK, McNatt J, Benedict CR, Anderson HV, Golino P, Murphee SS, Buja LM. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal formation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991; 88: 10624-8.
24. 24. Bauters C, Lablanche J, McFadden EP, Hamon M, Bertrand ME. Relation of coronary angioscopic findings at coronary angioplasty to angiographie restenosis. Circulation 1995; 92: 2473-9.
25. 25. De Groote, Bauters C, McFadden EP, Lablanche JM, Leroy F, Bertrand ME. Local lesion-related factors and restenosis after coronary angioplasty. Evidence from a quantitative angiographic study in patients with unstable angina undergoing double-vessel angioplasty. Circulation 1995; 91: 968-72.
26. 26. Ishiwata S, Tukada T, Nakanishi S, Nishiyma S, Seki A. Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-92.
27. 27. Sigel B, Swami V, Can A, Parsons RE, Golub RM, Kolecki R, Kitamura H. Intimal hyperplasia producing thrombus organization in an experimental venous thrombosis model. J Vasc Surg 1994; 19: 350-60.
28. 28. Haudenschild CC. Pathobiology of restenosis after angioplasty. Am J Med 1993; 94(Suppl.4A): 40S-4S.
29. 29. Schnitt SJ, Safian RD, Kuntz RE, Schmidt DA, Baim DS. Histologic findings in specimens obtained by percutaneous bidirectional coronary atherectomy. Hum Pathol 1992; 23: 415-20.
30. 30. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-93.
31. 31. Goldberg ID, Stemerman MB. Vascular permeation of platelet factor 4 after endothelial injury. Science 1980; 209: 611-2.
32. 32. Schwartz, SM, Majesky MW. Structure and function of the vessel wall. In: Colman W, Hirsh J, Marde VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia: Lippincott, 1994: 705-17.
33. 33. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86: 8412-6.
34. 34. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-32.
35. 35. Holmsen H. Platelet secretion and energy metabolism. In: Colman W, Hirsh J, Marde VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia: Lippincott, 1994: 524-45.
36. 36. Gaits F, Fourcade O, Le Balle F, Gueguen G, Gaigé B, Gassama-Diagne A, Fauvel J, Salles, J-P, Mauco G, Simon M-F, Chap H. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett 1997; 410: 54-8.
37. 37. Marcus AJ. Multicellular eicosanoid and other metabolic interactions of platelets and other cells. In: Colman W, Hirsh J, Marde VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott, 1994: 590-602.
38. 38. Ofosu FA, Longbin L, Freedman J. Control mechanisms in thrombin generation. Sem Thromb Hemost 1996; 22: 303-8.
39. 39. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986; 46: 155-69.
40. 40. Niewarowski S, Holt JC, Cook JJ. Biochemistry and physiology of secreted platelet proteins. In: Colman W, Hirsh J, Marde VJ, Salzman EW, eds. Hemostasis and thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott, 1994: 546-56.
41. 41. Di Corletto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1983; 80: 1919-23.
42. 42. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-18.
43. 43. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin C-H. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1985; 82: 4418-22.
44. 44. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem 1994; 269: 32023-6.
45. 45. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268: 14553-6.
46. 46. Malarkey K, Belham CM, Paul A, Graham A, McLees A, Scott PH, Plevin R. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J 1995; 309: 361-75.
47. 47. Obata H, Biro S, Arima N, Kaieda H, Kihara T, Eto H, Miyata M, Tanaka H. NF-kappa B is induced in the nuclei of cultured rat aortic smooth muscle cells by stimulation of various growth factors. Biochem Biophys Res Commun 1996; 224: 27-32.
48. 48. Jawien A, Bowen-Pope DF, Linder V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89: 507-11.
49. 49. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1988; 314: 488-500.
50. 50. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb 1993; 13: 1218-26.
51. 51. Lindner V, Giachelli CM, Schwartz SM, Reidy MA. A subpopulation of smooth muscle cells in rat arteries express PDGF-B chain mRNA. Circ Res 1995; 76: 951-7.
52. 52. Marijanowski MMH, Giese NA, Chronos NAF, Cui J, Hanson SR. Anti-PDGF beta-receptor antibody inhibits neointima formation in primates. Circulation 1997; 96(Suppl): 1-37.
53. 53. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75: 487-517.
54. 54. Owens GK. Role of alterations in the differentiated state of vascular smooth muscle cells in atherogenesis. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven, 1996: 401-20.
55. 55. Blank RS, Owens GK. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J Cell Physiol 1990; 142: 635-42.
56. 56. Corjay MH, Thompson MM, Lynch KR, Owens GK. Differential effects of platelet-derived growth factor-versus serum-induced growth on smooth muscle cell alpha-actin and nonmuscle beta-actin mRNA expression in cultured rat aortic smooth muscle cells. J Biol Chem 1989; 264: 10501-6.
57. 57. Corjay MH, Blank RS, Owens GK. Platelet-derived growth factor-induced destabilization of smooth muscle alpha-actin mRNA. J Cell Physiol 1990; 145: 391-7.
58. 58. Holycross BJ, Blank RS, Thompson MM, Peach MJ, Owens GK. Platelet-derived growth factor-BB-induced suppression of smooth muscle cell differentiation. Circ Res 1992; 71: 1525-32.
59. 2. Biochem J 1997; 327: 709-16.
60. 60. Rifkin DB, Kojima S, Abe M. TGF-beta: Structure function and formation. Thromb Haemost 1993; 70: 177-9.
61. 61. De Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978; 75: 4001-5.
62. 62. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor-beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989; 83: 4544-8.
63. 63. Assoian RK, Grotendorst GR, Miller DM, Sporn MB. Cellular transformation by coordinate action of three peptide growth factors from human platelets. Nature 1984; 309: 804-6.
64. 64. Assoian RK and Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102: 1217-23.
65. 65. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium. J Cell Biol 1988; 106: 1659-65.
66. 66. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V. Transforming growth factor type b. Rapid induction of angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167-71.
67. 67. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Am J Physiol 1993; 264: G179-86.
68. 68. Hayden MR, Reidy M. Many roads lead to atheroma. Nature Med 1995; 1: 22-3.
69. 69. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel JG. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-63.
70. 70. Agrotis A, Saltis J, Bobik A. Transforming growth factor-beta 1 gene activation and growth of smooth muscle from hypertensive rats. Hypertension 1994; 23: 593-9.
71. 71. Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J 1994; 299: 227-35.
72. 72. Morisaki N, Kawano M, Koyama N, Koshikawa T, Umemiya K, Saito Y, Yoshida S. Effects of transforming growth factor-beta I on growth of aortic smooth muscle cells. Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis 1991; 88: 227-34.
73. 73. Ouchi Y, Hirosumi J, Watanabe M, Hattori A, Nakamura T, Orimo H. Inhibitory effect of transforming growth factor-beta on epidermal growth factor-induced proliferation of cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1988; 157: 301-7.
74. 74. Owens GK, Geisterfer AA, Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988; 107: 771-80.
75. 75. Saltis J, Agrotis A, Bobik A. TGF-beta potentiates growth factorstimulated proliferation of vascular smooth muscle cells in genetic hypertension. Am J Physiol 1992; 263: C420-8.
76. 76. Hwang DL, Latus LJ, Lev-Ran A. Effects of platelet-contained growth factors (PDGF, EGF, IGF-1, and TGF-beta) on DNA synthesis in porcine aortic smooth muscle cells in culture. Exp Cell Res 1992; 200: 358-60.
77. 77. Janat MF, Liau G. Transforming growth factor beta 1 is a powerful modulator of platelet-derived growth factor action in vascular smooth muscle cells. J Cell Physiol 1992; 150: 232-42.
78. 78. Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor beta. Dev Biol 1996; 178: 430-45.
79. 79. Kirschenlohr HL, metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF beta. Cardiovasc Res 1995; 29: 848-55.
80. 80. Li Z, Alavi MZ, Moore S. The proliferation of neointimal smooth muscle cells cultured from rabbit aortic explants 15 weeks after de-endothelialization by a balloon catheter. Int J Exp Pathol 1994; 75: 169-77.
81. 81. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63: 515-24.
82. 82. Stouffer GA, Owens GK. TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest 1994; 93: 2048-55.
83. 83. Shah N, Groves AK, Anderson DJ. Alternative neural crest cell fates are instructively prompted by TGF beta superfamily members. Cell 1996; 85: 331-43.
84. 84. Olson EN, Sternberg E, Hu JS, Spizz G, Wilcox C. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 1986; 103: 1799-805.
85. 85. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-11.
86. 86. Shi Y, O'Brien JE Jr, Fard A, Zalewski A. Transforming growth factor-beta 1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol 1996; 16: 1298-305.
87. 87. Bjorkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb 1991; 11: 892-902.
88. 88. Katoh Y, Shimamoto T, Yamaguchi H. Transforming growth factor beta (TGF beta) stimulates smooth muscle myosin heavy chain (SMHC) gene expression through a cis-acting element that contains an Sp-l-binding site. Circulation 1997; 96:(Suppl.): 1-285.
89. 89. Orlandi A, Ropraz P, Gabbiani G. Proliferative activity and alpha-smooth muscle actin expression in cultured rat aortic smooth muscle cells are differentially modulated by transforming growth factor beta-1 and heparin. Exp Cell Res 1994; 214: 528-36.
90. 90. Hautmann MB, Madsen CS, Owens GK. A transforming growth factor beta (TGF beta) control element drives TGF beta-induced stimulation of smooth muscle alpha actin gene expression in concert with two CArG elements. J Biol Chem 1997; 272: 6332-40.
91. 91. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991; 88: 904-10.
92. 92. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 supress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-8.
93. 93. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SBI, Lembo NJ, Roubin GS, Sgoutas DS. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736-9.
94. 94. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993; 260: 1655-8.
95. 95. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nature Med 1995; 1: 74-9.
96. 96. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 1997; 34: 404-10.
97. 97. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. The epidermal growth factor. Cell Biol Int 1995; 19: 413-30.
98. 98. Bagby SP, O'NReilly MM, Kirk EA, Mitchell LH, Stenberg PE, Makler MT, Bakke AC. EGF is incomplete mitogen in porcine aortic smooth muscle cells: DNA synthesis without cell division. Am J Physiol 1992; 262: C578-88.
99. 99. Mitsumata M, Gamou S, Shimizu N, Yoshida Y. Response of atherosclerotic intimal smooth muscle cells to epidermal growth factor in vitro. Arterioscler Thromb 1994; 14: 1364-71.
100. 100. Bauriedel G, Heidemann P, Klingel K, Windstetter U, Hofling B, Kandolf R. In situ detection of EGF receptor mRNA in arteriosclerotic lesions in man: implications for the proliferative activity of smooth muscle cells. Z Kardiol 1992; 81: 519-24.
101. 101. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita T, Yamashita S, Matsuzawa Y, Taniguchi N. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 1995; 95: 404-11.
102. 102. Saltis J, Thomas AC, Agrotis A, Campbell JH, Campbell GR, Bobik A. Expression of growth factor receptors in arterial smooth muscle cells. Dependency on cell phenotype and serum factors. Atherosclerosis 1995; 118: 77-87.
103. 103. Pickering JG, Bacha PA, Weir L, Jekanowski J, Nichols CK, Isner JM. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. J Clin Invest 1993; 91: 724-9.
104. 104. Benzakour O, Kanthou C. Cellular and molecular events in atherogenesis: basis for pharmacological and gene therapy approaches to restenosis. Cell Pharmacol 1996; 3: 7-22.
105. 105. Bornfeld KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin and insulin analogues and insulin-like growth factor in the rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307-13.
106. 106. Banskota NK, Taub R, Zellner K, King GL. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 1989; 3: 1183-90.
107. 107. Thömmes KB, Hoppe J, Vetter H, Sachinidis A. The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signalling pathways. Exp Cell Res 1996; 226: 59-66.
108. 108. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 1990; 66: 1755-60.
109. 109. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment of restenosis? Circulation 1994; 89: 1511-7.
110. 110. Motani A, Rutherford C, Anggard EE, Ferns GA. Insulin-like growth factor binding protein-1 inhibits arterial smooth muscle cell proliferation in vitro but does dot reduce the neointimal response to balloon catheter injury. Atherosclerosis 1995; 118: 57-66.
111. 111. Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery 1991; 18: 197-225.
112. 112. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-18.
113. 113. Erlinge D, Yoo H, Edvinsson L, Reis DJ, Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs. other growth factors and sympathetic cotransmitters. Am J Physiol 1993; 265: H1089-97.
114. 114. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Peptides 1994; 50: 259-65.
115. 115. Wang DJ, Huang NN, Heppel LA. Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J Cell Physiol 1992; 153: 221-33.
116. 116. Erlinge D, You J, Wahlestedt C, Edvinsson L. Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cells. Eur J Pharmacol 1995; 289: 135-49.
117. 117. Yu S-M, Chen S-F, Lau Y-T, Yang C-M, Chen J-C. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells. Mol Pharmacol 1996; 50: 1000-9.
118. 118. Araki S-I, Kawahara Y, Fukuzaki H, Takai Y. Serotonin plays a major role in serum-induced phospholipase C-mediated hydrolysis of phosphoinositides and DNA synthesis in vascular smooth muscle cells. Atherosclerosis 1990; 83: 29-34.
119. 119. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle mitogenesis by serotonin. Proc Natl Acad Sci USA 1986; 83: 674-8.
120. 1-protein. Nature 1988; 335: 254-6.
121. 121. Seuwen K, Pousségur J. Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 985-90.
122. 122. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-80.
123. 123. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta 1989; 1001: 282-5.
124. 124. Watson SP, McConnell RT, Lapetina EG. Decanoyl lysophosphatidic acid induced platelet aggregation through an extracellular action. Evidence against a second messenger role of lysophosphatidic acid. Biochem J 1985; 232: 61-6.
125. 125. Jalink K, Hordijk PL, Moolenaar WH. Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator. Biochim Biophys Acta 1994; 1198: 185-96.
126. 126. Seewald S, Sachinidis A, Düsing R, Ko Y, Seul C, Epping P, Vetter H. Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells. Atherosclerosis 1997; 130: 121-31.
127. 127. Durieux ME, Lynch KR. Signalling properties of lysophosphatidic acid. Trends Pharmacol Sci 1993; 14: 249-54.
128. 2 in thrombin-induced platelet-rich plasma clots. Ann Hematol 1997; 74(Suppl.): 337.
129. 2 and involves upregulation of thromboxane receptor mRNA. Circulation 1998; 97: 589-595.
130. 2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 1997; 48: 42-91.
131. 2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. J Biol Chem 1994; 269: 5693-8.
132. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280-6.
133. 2 and vascular smooth muscle cell proliferation. Hypertension 1995; 26: 771-80.
134. 134. Uehara Y, Ishimitsu T, Kimura K, Ishii M, Ikeda T, Sugimoto T. Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats. Prostaglandins 1988; 36: 847-57.
135. 135. Ali S, Becker MW, Davis MG, Dorn GW II. Dissociation of vasoconstrictor-stimulated basic fibroblast growth factor expession from hypertrophic growth in cultured vascular smooth muscle cells: Relevant roles of protein kinase C. Circ Res 1994; 75: 836-43.
136. 136. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
137. 2 in vascular smooth muscle cells. Biochem Pharmacol 1990; 40: 2535-42.
138. 2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol 1997; 319: 327-32.
139. 2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. Atherosclerosis 1988; 72: 245-8.
140. 2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992; 263: H1331-8.
141. 2 stimulated signal transduction in vascular smooth muscle. J Pharmacol Exp Ther 1993; 265: 447-56.
142. 142. Craven PA, Stude RK, DeRubertis FR. Thromboxane/prostaglandin endoperoxide-induced hypertrophy of rat vascular smooth muscle cells is signaled by protein kinase C-dependent increase in transforming growth factor-beta. Hypertension 1996; 28: 169-76.
143. 2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast factor. J Biol Chem 1993; 268: 17397-403.
144. 144. Mann KG. Prothrombin and thrombin. In: Colman W, Hirsh J, Marde VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia: Lippincott, 1994: 184-99.
145. 145. Fager G. Thrombin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77: 645-50.
146. 146. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2nd, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-8.
147. 147. Glusa E, Paintz M, Zucker T-P, Schrör K. Thrombin receptor activating peptide-induced cellular effects: comparative studies on human platelet activation and endothelial-dependent relaxation of porcine pulmonary arteries. Agents Actions Suppl 1995; 45: 303-7.
148. 148. Bretschneider E, Wittpoth M, Weber A-A, Glusa E, Schrör K. Activation of NFkB is essential but not sufficient to stimulate mitogenesis of vascular smooth muscle cells. Biochem Biophys Res Commun 1997; 235: 365-8.
149. 149. Bretschneider E, Wittpoth M, Weber A-A, Glusa E, Schrör K. Thrombin but not thrombin receptor activating peptide is mitogenic for coronary artery smooth muscle cells. Thromb Res 1997; 87: 493-7.
150. 150. Hérbert JM, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. FEBS Lett 1992; 301: 155-8.
151. 151. Kanthou C, Benzakour O, Patel G, Deadman J, Kakkar VV, Lupu F. Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells. Thromb Haemost 1995; 74: 1340-7.
152. 152. McNamara CA, Sarembock IJ, Gimple LW, Fenton II, Owens GK. Human thrombin receptor-activating peptide induced proliferation of cultured vascular smooth muscle cells exhibits species specifity. Drug Dev Res 1995; 35: 7-12.
153. 153. Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq J-P, Pousségur J. Synthetic α-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Mol Biol Cell 1992; 3: 95-102.
154. 154. Berk BC, Taubman MB, Cragoe EJ Jr, Fenton JW 2nd, Griendling KK. Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and -independent pathways. J Biol Chem 1990; 265: 17334-40.
155. 155. Kanthou C, Benzakour O. Cellular effects of thrombin and their signalling pathways. Cell Pharmacol 1995; 2: 293-302.
156. 156. Nakajima T, Kitajima I, Shin H, Takasaki I, Shigeta K, Abeyama K, Yamashita Y, Tokioka T, Soejima Y, Maruyama I. Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem Biophys Res Commun 1994; 204: 950-5.
157. 157. Ishii K, Hein L, Kobika B, Coughlin SR. Kinetics ot thrombin receptor cleavage on intact cells: Relation to signaling. J Biol Chem 1993; 268: 9780-6.
158. 158. Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin-induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Physiol 1995; 268: C1141-7.
159. 159. McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M. Barry W, Gimple LW, Powers ER, Owens GK. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost 1996; 22: 139-44.
160. 160. Kanthou C, Parry G, Wijelath E, Kakkar VV, Demoliou-Mason C. Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. FEBS Lett 1992; 314: 143-8.
161. 161. Nakano T, Raines EW, Abraham JA, Wenzel FG, Higashiyama S, Klagsbrun M, Ross R. Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells. J Biol Chem 1993; 268: 22941-7.
162. 162. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by thrombin in vascular smooth muscle cells. Circ Res 1992; 71: 1285-93.
163. 163. Bachhuber BG, Sarembock IJ, Gimple LW, Owens GK. Alpha-thrombin induces transforming growth factor beta, mRNA and protein in cultured vascular smooth muscle cells via a proteolytically activated receptor. J Vasc Res 1997; 34: 41-8.
164. 164. Stouffer GA, Sarembock IJ, McNamara CA, Gimple LW, Owens GK. Thrombin-induced mitogenesis of vascular SMC is partially mediated by autocrine production of PDGF-AA. Am J Physiol 1993; 256: C806-11.
165. 165. Delafontaine P, Anwar A, Lou H, Ku L. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest 1996; 97: 139-45.
166. 166. Weiss RH, Maduri M. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. 1993; 268: 5724-7.
167. 167. Pawlowski JE, Taylor DS, Valentine M, Hail ME, Ferrer P, Kowala MC, Molloy CJ. Stimulation of activin A expression in rat aortic smooth muscle cells by thrombin and angiotensin II correlates with neointimal formation in vivo. J Clin Invest 1997; 100: 639-49.
168. 168. Vernon S, Sarembock IJ, Owens GK. Thrombin-induced proliferation in cultured smooth muscle cells is not associated with downregulation of smooth muscle α-actin gene expression. Circulation 1993; 88: 1-189.
169. 169. Agnelli G. Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis. Cariovasc Res 1996; 31; 232-4.
170. 170. Hatton MW, Moar SL, Richardson M. De-endothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499-508.
171. 171. Walters TK, Gorog DA, Wood RFM. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerosis process. J Vasc Res 1994; 31: 173-7.
172. 172. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
173. 173. Nelken NA, Soifer SJ, O'Keefe J, Vu T-K, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-21.
174. 174. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75: 1029-38.
175. 175. Zhong C, Hayzer DJ, Corson MA, Runge MS. Molecular cloning of the rat vascular smooth muscle thrombin receptor: evidence for in vitro regulation by basic fibroblast growth factor. J Biol Chem 1992; 267: 16975-9.
176. AB. Circulation 1997; 96: 3888-96.
177. 177. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
178. 178. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H, Gafner V, Aleksic I, Althaus U, Lüscher TF. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 1997; 95: 1870-6.
179. 179. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
180. 180. Unterberg C, Meyer T, Wiegand V, Kreuzer H, Buchwald AB. Proliferative response of human and minipig smooth muscle cells after coronary angioplasty to growth factors and platelets. Basic Res Cardiol 1996; 91: 407-17.
181. 181. Weber A-A, Zucker T-P, Schrör K. Thrombozytenmembranen induzieren Mitogenese in glatten Gefäβmuskelzellen - ein neuer, PDGF-unabhängiger Mechanismus für chronische Proliferation nach Gefäβverletzung? Z Kardiol 1997; 86(Suppl 2): 1189.
182. 182. Yamamoto M, Yamamoto K. Growth regulation in primary culture of rabbit arterial smooth muscle cells by platelet-derived growth factor, insulin-like growth factor-I, and epidermal growth factor. Exp Cell Res 1994; 212: 62-8.
183. 183. Nishio E, Watanabe Y. Transforming growth factor beta is a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for catalase activity and glutathione peroxidase activity. Biochem Biophys Res Commun 1997; 232: 1-4.
184. 184. Saltis J, Bobik A. Regulation by protein kinase C of transforming growth factor-beta 1 action on the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1996; 23: 573-5.
185. 185. Blay J, Hollenberg MD. Heterologous regulation of EGF receptor function in cultured aortic smooth muscle cells. Eur J Pharmacol 1989; 172: 1-7.
186. 2 receptor: molecular cloning, expression, and functional characterization. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 357: 10-16.
187. 187. Schini-Kerth VB, Fisslthaler B, Van Obberghen-Schilling E, Busse R. Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Circulation 1996; 93: 2170-7.
188. 188. Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221: 273-4.
189. 189. Vanhoutte PM. Platelets, endothelium and blood vessel wall. Experientia 1988; 44: 105-8.
190. 2 receptors on human endothelial cells. Circ Res 1993; 72: 958-865.
191. 2) and atherosclerosis. In: Rubanyi GM, ed. The Endothelium in Clinical Practice: Source and Target of Novel Concepts and Therapies. New York: Marcel Dekker, 1997; 1-44.
192. 192. Scott-Burden T, Schini VB, Hlizondo E, Junquero DC, Vanhoutte PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitic oxide by cultured smooth muscle cells: effects on cell proliferation, Circ Res 1992; 71: 1088-100.
193. 193. Coughlin SR, Moskowitz MA, Zetter BR, Antoniades HN, Levine L. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature 1980; 288: 600-2.
194. 1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998; 345: 213-220.
195. 195. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14: 1021-31.
196. 196. Weber A-A, Zucker T-P, Hasse A, Bönisch D, Wittpoth M, Schrör K. Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Basic Res Cardiol 1998; 93 (Suppl. 3): 54-7.
197. 197. Zembowich A, Jones SL, Wu KK. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidycholine. J Clin Invest 1995; 96: 1688-92.
198. 198. Otto JC, Smith WL. Prostaglandin endoperoxide synthases-1 and -2. J Lipid Mediators Cell Signalling 1995; 12: 139-56.
199. 199. Habib A, Créminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of expression of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxy-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268: 23448-54.
200. 200. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-8.
201. 201. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
202. 202. Lee SH, Soyool E, Chanmugam P, Hart S, Sund W, Zhong H, Iliou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-8.
203. 203. Pritchard KA, O'Banion MK, Miano JM, Vlasic N, Bhatia UG, Young DA, Stemerman MB. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem 1994; 269: 8504-9.
204. 204. Eldor E, Falcone DJ, Hajjar DP, Minick CR, Weksler BB. Recovery of prostacyclin production by deendothelialized rabbit aorta: critical role of neointimal smooth muscle cells. J Clin Invest 1981; 67: 735-41.
205. 205. Schrör K, Weber A-A. Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 1997; 48: 62-90.
206. 206. Habenicht AJR, Salbach P, Goerig M, Zeh W, Janssen-Timmen U, Blattner C, King WC, Glomset JA. The LDL-receptor pathway delivers free arachidonic acid for eicosanoid formation in cells stimulated with platelet-derived growth factor. Nature 1990; 345: 634-6.
207. 207. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
208. 208. Bunting S, Gryglewski S, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913.
209. 209. Hechtmann DH, Kroll MH, Gimbrone MA, Schafer AI. Platelet interaction with vascular smooth muscle in synthesis of prostacyclin. Am J Physiol 1991; 260: H1544-51.
210. 210. Force T, Milani R, Hibberd P, Lorenz R, Uedelhoven W, Leaf A, Weber P. Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Circulation 1991; 84: 2286-93.
211. 211. Pomerantz KB, Hajjar DP. Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis 1989; 9: 413-60.
212. 212. Sinzinger H, Fitscha P. Epoprostenol and platelet deposition in atherosclerosis (letter). Lancet 1984; i: 905-6.
213. 2 is important in atherosclerosis. Adv Prostagl Thromb Leukotr Res 1987; 17: 216-8.
214. 214. Asada Y, Kisanuki A, Hatakeyama K, Takahama S, Koyama T, Kurozumi S, Sumiyoshi A. Inhibitory effects of prostacyclin analogue, TFC 132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro. Prostagl Leukotr Essent Fatty Acids 1994; 51: 245-8.
215. 2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol 1995; 25: 947-52.
216. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Hear J 1994; 71: 7-15.
217. 217. Isaka Y, Hande N, Imaizumi M, Kimura K, Kamada T. Effect of TRK-100, a stable orally active prostacyclin analogue, on platelet function and platelet size in atherothrombotic strokes. Thromb Haemost 1991; 65: 344-50.
218. 218. Darius H, Nixdorff U, Zander J, Rupprecht HJ, Erbel R, Meyer J. Effects of ciprostene on restenosis rate during therapeutical transluminal coronary angioplasty. Agents Actions 1992; 37: 305-11.
219. 219. Ahlner J, Andersson RGG, Tofgard K, Axelsson KL. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 1991; 43: 351-423.
220. 220. Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55: 649-54.
221. 221. Weber A-A, Strobach H, Schrör K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol 1993; 247: 29-37.
222. 222. Weber A-A, Neuhaus T, Seul C, Düsing R, Schrör K, Sachinidis A, Vetter H. Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells. Eur J Pharmacol 1996; 309: 209-13.
223. 223. Yu S-M, Chen S-F, Lau Y-T, Yang C-M, Chen J-C. Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells. Mol Pharmacol 1996; 50: 1000-9.
224. 2 analogues and an NO (EDRF) donor: A comparison between platelets in healthy and diabetic subjects. Platelets 1994; 5: 45-52.
225. 225. Groves PH, Penny WJ, Cheadle HJ, Lewis MJ. Exogenous nitric oxide inhibits in vivo platelet adhesion following balloon angioplasty. Cardiovasc Res 1992; 26: 615-9.
226. 226. Groves PH, Lewis MJ, Cheadle HA, Penny WJ. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation 1993; 87: 590-7.
227. 227. Fukuo K, Inoue T, Morimoto S, Nakahashi T, Yasuda O, Kitano S, Sasada R, Ogihara T. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. A possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest 1995; 95: 669-76.
228. 228. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of 1-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-72.
229. 229. McNamara DB, Bedi H, Aurora L, Tenta L, Ignarro LJ, Kadowitz PJ, Akers DL. L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993; 193: 291-6.
230. 230. Guo JP, Siegfried MR, Lefer AM. Beneficial effects of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994; 75: 77-84.
231. 231. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995; 96: 2630-8.
232. 232. Kojda G, Stein D, Kottenberg E, Schanaith M, Noack E. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25: 763-73.
233. 233. Lablanche JM, Grollier G, Lusson JR, Bassand JP, Drobinski G, Bertrand B, Battaglia S, Desveaux B, Juilliere Y, Juliard JM, Methger JP, Coste P, Quiret JC, Dubois-Rande JL, Crochet PD, Letac B, Boschar J, Virol P, Finet G, LeBreton H, Livarek B, Leclerq F, Beard T, Giraud T, Bertrand ME. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Circulation 1997; 95: 83-9.
234. 234. Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.
235. 235. Schrör K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23: 349-56.
236. 236. Patrono C. Aspirin and human platelets: From clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 1989; 10: 453-8.
237. 237. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by endogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood 1988; 71: 1366-74.
238. 238. Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
239. 239. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
240. 2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 1988; 157: 733-9.
241. 241. Muck S, Weber A-A, Schrör K. Effects of terbogrel on platelet function and transcellular eicosanoid transfer. Eur J Pharmacol, 1998; 344: 45-48.
242. 242. Catella-Lawson F, FitzGerald GA. Therapeutic aspects of platelet pharmacology. In: von Bruchhausen F, Walter U, eds. Platelets and Their Factors. Handbook of Experimental Pharmacology, Vol 126. Berlin: Springer, 1996; 719-36.
243. 243. Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drug Ther 1992; 6: 29-33.
244. 2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptanoic acid (V-4151), for prevention of restenosis after coronary angioplasty. Jnp Circ J 1991; 55: 324-9.
245. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194-200.
246. 2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Circulation 1991; 84: 1568-80.
247. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30.
248. 248. Schrör K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998; 3: 247-51.
249. 249. Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannuci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694-9.
250. 250. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla Volta S. Adenosine diphosphate (ADP) induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost 1986; 56: 147-50.
251. 251. Hérbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993; 13: 1171-9.
252. 252. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina, a controlled multicenter clinical trial. Circulation 1990; 82: 17-26.
253. 253. Bellavance A, for the Ticlopidine Aspirin Stroke Study Group. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. Stroke 1993; 24: 1452-7.
254. 254. Gent M, Blakeley JA, Easton JD, and the CATS Group. The Canadian-American Ticlopidin Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
255. 255. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. Ticlopidine Aspirin Stroke Study group: a randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7.
256. 256. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aortocoronary bypass graft occlusion - Beneficial effects of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987; 94: 773-83.
257. 257. Becquemin J-P, for the Etude de la Ticlopidine aprés Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurge. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726-31.
258. 258. Kastrati A, Schulen H, Hausleiter J, Walter H, Zitzmann-Roth E, Hadamitzky M, Elezi S, Ulm K, Dirschinger J, Neumann FJ, Schömig A. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997; 96: 462-7.
259. 259. Gent M and CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
260. 260. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
261. 261. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-6.
262. 262. Azrin MA, Ling S, Chen Q, Pawashe A, Migliaccio F, Homer R, Todd M, Ezekowitz MD. Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. Circ Res 1994; 75: 268-77.
263. 263. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tscheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Lancet 1994; 343: 881-6.
264. 264. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1748-9.
265. 265. Tscheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol 1997; 80(4A): 21B-8B.
266. 266. The RESTORE Investigators. Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96: 1445-53.
267. 267. Glusa E. Hirudin and platelets. Semin Thromb Hemost 1991; 17: 122-5.
268. 268. Markwardt F. The comeback of hirudin as an antithrombotic agent. Semin Thromb Hemost 1991; 17: 79-82.
269. 269. Grutter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 8: 2361-5.
270. 270. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJ, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-84.
271. 271. Ragosta M, Barry WL, Gimple LW, Gertz SD, McCoy KW, Stouffer GA, McNamara CA, Powers ER, Owens GK, Sarembock IJ. Effect of thrombin inhibition on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Circulation 1996; 93: 1194-200.
272. 272. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-43.
273. 273. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the HELVETICA Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63.
274. 274. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26(Suppl 1): 76-82.
275. 275. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193-213.